This study used an online survey to assess how psychological distress has changed over the course of the coronavirus disease 2019 (COVID-19) pandemic from April to July 2020.
This JAMA Insights review summarizes the pathophysiology underlying the thrombotic diathesis characteristic of acute SARS-CoV-2 infection and current recommendations for the prevention, diagnosis, and management of the most common thrombotic complications in COVID-19, including acute myocardial infarction (AMI), ischemic stroke, and venous thromboembolism (VTE).
This Viewpoint summarizes evidence suggesting that, counter to expectation, older adults as a group may be more resilient to the anxiety, depression, and stress-related mental health disorders characteristic of younger populations during the COVID-19 pandemic.
A 40-year-old woman with dizziness and imbalance, a petechial rash on her palms and soles, and a right thumbnail splinter hemorrhage had acute right cerebellar infarcts with a left atrial mass on CT angiogram. What is the diagnosis and what would you do next?
This Viewpoint proposes that a polypill combination of a β-blocker, renin angiotensin inhibitor, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor might be the most efficient way to deliver guideline-directed HFrEF therapy, and proposes a research roadmap to design and evaluate the pill and implementation strategies for getting it to patients.
This Viewpoint proposes that Medicare claims data could inform the rollout of a COVID-19 vaccination program in the US, including notifying beneficiaries of their risk and prioritization and supporting efforts to allocate the vaccine and monitor its uptake, immunogenicity, and safety.
This Viewpoint uses clinical observations of the natural course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to propose 3 phases of illness: acute infection (what people commonly refer to with the COVID-19 designation); postacute hyperinflammatory illness (referred to clinically as multisystem inflammatory syndrome); and late inflammatory sequelae, manifest as enduring cardiac, neurological, and psychological symptoms.
This Medical News article examines how studying the characteristics of long-term pancreatic cancer survivors might improve treatment and boost survival for others who have the disease
This Viewpoint summarizes a National Academy of Sciences, Engineering, and Medicine (NASEM) consensus panel report recommending ways to reduce populations in prisons and jails as a means to mitigate SARS-CoV-2 transmission and the roles clinicians, health systems, and insurers can play in in process.
This randomized trial examines the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.
This cohort study assesses adherence to evidence-based fractional flow reserve (FFR) thresholds for percutaneous coronary intervention in Canada between 2013 and 2018, and associations of percutaneous coronary intervention with major adverse clinical outcomes for patients with FFR measures above and beneath ischemic thresholds.
This Viewpoint reviews the rare incidence of nosocomial SARS-CoV-2 infection and discusses ways it can be minimized, including use of surgical masks, proper ventilation, physical distancing, eye protection, regular testing, and the availability of sick leave for health care workers.
This Viewpoint proposes criteria for more effective COVID-19 testing strategies to manage population transmission, including use of rapid antigen tests and self-administered nasal and salivary tests, emphasizing that more effective testing alone cannot control the pandemic without continued public health interventions, such as mask wearing, physical distancing, and avoidance of large gatherings.
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects vs placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction–confirmed mild coronavirus disease 2019 (COVID-19) illness.
This Viewpoint discusses questions about clinical indication, supply, distribution, and cost and coverage that will need to be resolved if monoclonal antibodies are be granted Emergency Use Authorization or licensure and become available as treatment for COVID-19.
In this Viewpoint, Fauci and NIAID colleagues review leading candidates for treatment of mild to moderate coronavirus disease 2019 (COVID-19) to prevent disease progression and longer-term complications, including emerging antiviral drugs, immune-modulating agents, and antibody-based therapies, and the challenges of developing randomized trials to rapidly evaluate the safety and efficacy of each.
This Medical News article discusses the health implications of severe acute respiratory syndrome coronavirus 2 infection among young and middle-aged adults.
This randomized trial compares the effects of hydroxychloroquine vs placebo on clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with coronavirus disease 2019 (COVID-19).
This JAMA Clinical Guidelines Synopsis summarizes the US Multi-Society Task Force on Colorectal Cancer’s 2020 recommendations for follow-up after colonoscopy and polypectomy.
This Viewpoint discusses possible parallels between the distortion in sensory information and faulty monitoring of ideas characteristic of some patients with neurodegenerative diseases (dementia with Lewy bodies and Capgras syndrome, frontotemporal dementia) and the creation and maintenance of false conspiratorial beliefs about the COVID-19 pandemic in healthy populations that has hobbled an effective national response in the US.
This JAMA Insights Clinical Update discusses the importance of established influenza prevention and control measures, including influenza vaccination and antiviral treatment, as the Global North enters its first influenza season in the COVID-19 pandemic.
This JAMA Patient Page describes the groups of people who are at high risk of complications from influenza infection, how to reduce risk through vaccination, and steps high-risk people should take if they develop influenza symptoms.
Create a personal account or sign in to: